These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38113075)

  • 61. Polypharmacology in Precision Oncology: Current Applications and Future Prospects.
    Antolin AA; Workman P; Mestres J; Al-Lazikani B
    Curr Pharm Des; 2016; 22(46):6935-6945. PubMed ID: 27669965
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Computational polypharmacology: a new paradigm for drug discovery.
    Chaudhari R; Tan Z; Huang B; Zhang S
    Expert Opin Drug Discov; 2017 Mar; 12(3):279-291. PubMed ID: 28067061
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Polypharmacology Within the Full Kinome: a Machine Learning Approach.
    Jones D; Bopaiah J; Alghamedy F; Jacobs N; Weiss HL; de Jong WA; Ellingson SR
    AMIA Jt Summits Transl Sci Proc; 2018; 2017():98-107. PubMed ID: 29888050
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent advances in multitarget-directed ligands via in silico drug discovery.
    Maddeboina K; Yada B; Kumari S; McHale C; Pal D; Durden DL
    Drug Discov Today; 2024 Mar; 29(3):103904. PubMed ID: 38280625
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
    Panicker RC; Chattopadhaya S; Coyne AG; Srinivasan R
    Adv Exp Med Biol; 2019; 1163():253-278. PubMed ID: 31707707
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multimodal multi-task deep neural network framework for kinase-target prediction.
    Hua Y; Luo L; Qiu H; Huang D; Zhao Y; Liu H; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2023 Dec; 27(6):2491-2503. PubMed ID: 36369613
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification.
    Lieshout R; Faria AVS; Peppelenbosch MP; van der Laan LJW; Verstegen MMA; Fuhler GM
    Mol Med; 2022 Jun; 28(1):74. PubMed ID: 35764936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epigenetic polypharmacology: A new frontier for epi-drug discovery.
    Tomaselli D; Lucidi A; Rotili D; Mai A
    Med Res Rev; 2020 Jan; 40(1):190-244. PubMed ID: 31218726
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors.
    Phatak SS; Zhang S
    Pac Symp Biocomput; 2013; ():29-40. PubMed ID: 23424109
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.
    Hu S; Jiang C; Gao M; Zhang D; Yao N; Zhang J; Jin Q
    Eur J Med Chem; 2023 May; 253():115334. PubMed ID: 37037136
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.
    Xie L; Kassner M; Munoz RM; Que QQ; Kiefer J; Zhao Y; Mousses S; Yin HH; Von Hoff DD; Han H
    Biochem Pharmacol; 2012 Feb; 83(4):452-61. PubMed ID: 22100984
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?
    Christmann-Franck S; van Westen GJ; Papadatos G; Beltran Escudie F; Roberts A; Overington JP; Domine D
    J Chem Inf Model; 2016 Sep; 56(9):1654-75. PubMed ID: 27482722
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Web-Based Tools for Polypharmacology Prediction.
    Awale M; Reymond JL
    Methods Mol Biol; 2019; 1888():255-272. PubMed ID: 30519952
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types.
    Berginski ME; Joisa CU; Golitz BT; Gomez SM
    PLoS Comput Biol; 2023 Feb; 19(2):e1010888. PubMed ID: 36809237
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meta-learning-based Inductive logistic matrix completion for prediction of kinase inhibitors.
    Du M; Xie X; Luo J; Li J
    J Cheminform; 2024 Apr; 16(1):44. PubMed ID: 38627866
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
    Verkhivker GM
    Bioinformatics; 2007 Aug; 23(15):1919-26. PubMed ID: 17537753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Developing kinase inhibitors for malaria: an opportunity or liability?
    Mogwera KSP; Chibale K; Arendse LB
    Trends Parasitol; 2023 Sep; 39(9):720-731. PubMed ID: 37385921
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
    Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
    J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.